Karolinska Development Management

Management criteria checks 4/4

Karolinska Development's CEO is Viktor Drvota, appointed in Jun 2017, has a tenure of 6.83 years. total yearly compensation is SEK4.73M, comprised of 62.9% salary and 37.1% bonuses, including company stock and options. directly owns 0.078% of the company’s shares, worth €27.29K. The average tenure of the management team and the board of directors is 3.9 years and 3.2 years respectively.

Key information

Viktor Drvota

Chief executive officer

kr4.7m

Total compensation

CEO salary percentage	62.9%
CEO tenure	6.8yrs
CEO ownership	0.08%
Management average tenure	3.9yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Viktor Drvota's remuneration changed compared to Karolinska Development's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr5m	kr3m	kr5m
Sep 30 2023	n/a	n/a	kr17m
Jun 30 2023	n/a	n/a	-kr41m
Mar 31 2023	n/a	n/a	-kr87m
Dec 31 2022	kr6m	kr3m	-kr88m
Sep 30 2022	n/a	n/a	-kr118m
Jun 30 2022	n/a	n/a	-kr72m
Mar 31 2022	n/a	n/a	kr166m
Dec 31 2021	kr5m	kr3m	kr171m
Sep 30 2021	n/a	n/a	kr276m
Jun 30 2021	n/a	n/a	kr108m
Mar 31 2021	n/a	n/a	-kr106m
Dec 31 2020	kr5m	kr3m	-kr207m
Sep 30 2020	n/a	n/a	kr35m
Jun 30 2020	n/a	n/a	kr190m
Mar 31 2020	n/a	n/a	kr195m
Dec 31 2019	kr6m	kr3m	kr303m
Sep 30 2019	n/a	n/a	-kr11m
Jun 30 2019	n/a	n/a	kr8m
Mar 31 2019	n/a	n/a	kr32m
Dec 31 2018	kr5m	kr3m	kr31m
Sep 30 2018	n/a	n/a	kr48m
Jun 30 2018	n/a	n/a	kr238m
Mar 31 2018	n/a	n/a	kr185m
Dec 31 2017	kr5m	kr1m	kr180m

Compensation vs Market: Viktor's total compensation ($USD434.74K) is about average for companies of similar size in the German market ($USD406.04K).

Compensation vs Earnings: Viktor's compensation has been consistent with company performance over the past year.

CEO

Viktor Drvota (58 yo)

6.8yrs

Tenure

kr4,733,000

Compensation

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Viktor Drvota	Chief Executive Officer	6.8yrs	kr4.73m	0.078% SEK 27.3k
Hans Toll	Chief Financial Officer	1.5yrs	no data	0.013% SEK 4.5k
Per Aniansson	Investment Director	3.1yrs	no data	0.059% SEK 20.8k
Eva Montgomerie	Head of Accounting	10.5yrs	no data	0.012% SEK 4.3k
John Öhd	Chief Scientific Officer & Venture Partner	3.8yrs	no data	no data
Johan Dighed	Chief Legal Officer & Deputy CEO	3.9yrs	no data	0.15% SEK 52.0k
Yan Cheng	President of Asia	6.8yrs	no data	0.0093% SEK 3.3k
Hans Wigzell	Senior Strategic Advisor	no data	kr500.00k	no data
Tse Ping	Senior Strategic Advisor	no data	no data	no data
Linda Spahiu	Investment Manager	no data	no data	0.0037% SEK 1.3k
Mikaela Sörman	Investment Manager	no data	no data	0.0037% SEK 1.3k

3.9yrs

Average Tenure

55yo

Average Age

Experienced Management: 2I9's management team is considered experienced (3.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Anna Lefevre Skjoldebrand	Independent Director	3.2yrs	kr200.00k	no data
Y. Y. Tse	Director	7.3yrs	no data	no data
Bjorn Cochlovius	Independent Chairman	3.8yrs	kr400.00k	no data
Ben Toogood	Director	3.2yrs	kr178.00k	0.024% SEK 8.3k
Philip Duong	Director	2.3yrs	kr200.00k	no data

3.2yrs

Average Tenure

47yo

Average Age

Experienced Board: 2I9's board of directors are considered experienced (3.2 years average tenure).

Karolinska Development Management

Management criteria checks 4/4

Key information

Recent management updates

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought €7.2k worth of stock

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Karolinska Development AB Announces Chief Financial Officer Changes

Less than half of directors are independent

Recent updates

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought €7.2k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: €0.21

New 90-day low: €0.23

New 90-day low: €0.23

New 90-day low - €0.23

Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age